The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The firm's 14 percent growth in molecular diagnostics sales was driven primarily by continued strength across its Aptima women's health products globally.
The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.
The company also announced that it has received New York State Department of Health conditional approval for three women's health molecular diagnostic tests.
Cepheid said this week that it has launched Xpert HPV, a one-hour molecular test for cervical cancer-related human papillomaviruses, in Europe after receiving CE IVD marking.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
